Clin Nutr Res.  2014 Jan;3(1):17-23. 10.7762/cnr.2014.3.1.17.

Circulating Concentrations of C-Peptide and Colorectal Adenoma

• Choi YJ
• Kim YH
• Cho CH
• Kim SH
• Lee JE

• KMID: 2279617
• DOI: http://doi.org/10.7762/cnr.2014.3.1.17

Abstract

Hyperinsulinemia may increase the risk of colorectal neoplasia because of its mitogenic and antiapoptotic properties, which have a growth-promoting effect. We examined the association between circulating concentrations of C-peptide, a biomarker of insulin secretion, and colorectal adenoma prevalence in a case-control study of Korean adults. A total of 364 participants (112 cases and 252 controls) were included. Participants who underwent a colonoscopy completed questionnaires and provided blood samples. We used multivariate logistic regression models to obtain odds ratios (ORs) and 95% confidence intervals (CIs) for colorectal adenoma. Circulating concentrations of C-peptide were not associated with colorectal adenoma; the multivariate OR (95% CI) was 0.95 (0.51-1.75) comparing the highest tertile with the lowest tertile (p for trend = 0.91). When we used a conditional logistic regression model by fasting status and sex matching, there was still no association (OR = 0.92; 95% CI = 0.43-1.99) when comparing the highest tertile with the lowest tertile. We observed no association between circulating concentrations of C-peptide and colorectal adenoma prevalence in Korean adults.

Keyword

C-peptide; Colorectal adenoma; Hyperinsulinemia

MeSH Terms

Adenoma*
Adult
C-Peptide*
Case-Control Studies
Colonoscopy
Fasting
Humans
Hyperinsulinism
Insulin
Logistic Models
Odds Ratio
Prevalence
Surveys and Questionnaires
C-Peptide
Insulin

Reference

1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013; 45:1–14.

2. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010; 101:1286–1291.

3. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004; 262:247–260.

4. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res. 2003; 35:694–704.

5. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002; 94:972–980.

6. Tran TT, Naigamwalla D, Oprescu AI, Lam L, McKeown-Eyssen G, Bruce WR, Giacca A. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology. 2006; 147:1830–1837.

7. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res. 1996; 68:183–223.

8. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 1984; 33:486–494.

9. Autier P, Koechlin A, Boniol M, Mullie P, Bolli G, Rosenstock J, Boyle P. Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. Cancer Causes Control. 2013; 24:873–883.

10. Lai GY, Helzlsouer KJ, Clipp SL, Rifai N, Platz EA. Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev Res (Phila). 2010; 3:1334–1341.

11. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjønneland A, Halkjær J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, Teucher B, Becker S, Sluik D, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Vineis P, Panico S, Rodríguez L, Duell EJ, Molina-Montes E, Dorronsoro M, Huerta JM, Ardanaz E, Jeurnink SM, Beulens JW, Peeters PH, Sund M, Ye W, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboli E, Romaguera D, Bueno-de-Mesquita HB, Kaaks R. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia. 2011; 54:3037–3046.

12. Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, Tjønneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Chang-Claude J, Boeing H, Schulz M, Benetou V, Trichopoulou A, Trichopoulos D, Palli D, Berrino F, Tumino R, Mattiello A, Vineis P, Quirós JR, Agudo A, Sánchez MJ, Larrañaga N, Navarro C, Ardanaz E, Buenode-Mesquita HB, Peeters PH, van Gils CH, Bingham S, Khaw KT, Key T, Slimani N, Riboli E, Kaaks R. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007; 120:2656–2664.

13. Chen L, Li L, Wang Y, Li P, Luo L, Yang B, Wang H, Chen M. Circulating C-peptide level is a predictive factor for colorectal neoplasia: evidence from the meta-analysis of prospective studies. Cancer Causes Control. 2013; 24:1837–1847.

14. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Japan Public Health Center-based Prospective Study Group. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer. 2007; 120:2007–2012.

15. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. Int J Obes (Lond). 2012; 36:440–447.

16. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev. 2012; 21:411–416.

17. Le Marchand L, Wang H, Rinaldi S, Kaaks R, Vogt TM, Yokochi L, Decker R. Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol Biomarkers Prev. 2010; 19:1471–1477.

18. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2006; 15:750–755.

19. Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control. 2010; 21:1–10.

20. Vidal AC, Lund PK, Hoyo C, Galanko J, Burcal L, Holston R, Massa B, Omofoye O, Sandler RS, Keku TO. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer. 2012; 12:389.

21. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23:824–854.

22. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006; 17:328–336.

23. Goalstone ML, Wall K, Leitner JW, Kurowski T, Ruderman N, Pan SJ, Ivy JL, Moller DE, Draznin B. Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals. Diabetologia. 1999; 42:310–316.

24. Burgering BM, Medema RH, Maassen JA, van de Wetering ML, van der Eb AJ, McCormick F, Bos JL. Insulin stimulation of gene expression mediated by p21ras activation. EMBO J. 1991; 10:1103–1109.

25. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004; 96:546–553.